by Lance Smith | Sep 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Applied Molecular Transport (AMT), a clinical- stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 1b portion of a first-in-human clinical trial designed to evaluate the safety and tolerability of AMT-101, a novel oral...by Lance Smith | Sep 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Histogen, Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, today announced its plans for clinical development of three key product candidates during the Company’s presentation at the HC...by Lance Smith | Sep 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Sept. 9, 2019 13:00 UTC Successful completion of Fractyl’s first sham-controlled, multicenter clinical trial of Revita DMR to support EU commercial launch and inform U.S. pivotal clinical trial Revita-2 data support Revita DMR as a non-pharmacological intervention...by Lance Smith | Sep 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform
MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2 randomized, double-blind clinical trial comparing contezolid acefosamil (MRX-4) with linezolid for the treatment of acute bacterial skin and skin structure...by Lance Smith | Sep 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is being evaluated for the...by Lance Smith | Sep 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform
CytoDyn Inc. (OTC.QB:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has allowed a...